Abstract PR011: Real-world efficacy of immune checkpoint inhibitors when used in a selected population of pediatric solid cancers – A retrospective multicenter study
Clinical trials evaluating immune checkpoint inhibitors (ICIs) in unselected childhood cancers have shown low response rates, excluding Hodgkin lymphoma. We sought to describe the real-world antitumor activity and toxicity of ICIs in children, adolescents, and young adults (CAYAs) with solid tumors selected based...